Immune-Mediated Antitumor Effect By VEGFR2 Selective Inhibitor For Gastric Cancer

BACKGROUND: It was previously reported that targeting vascular epithelial growth factor (VEGF)/VEGFR could modulate the antitumor immunity. VEGFR2 inhibitor YN968D1 is a highly selective VEGFR2 inhibitor and was approved for the treatment of late-stage gastric cancer in 2014, but its role in antitum...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ju, Yan, Jing, Shao, Jie, Xu, Qiuping, Meng, Fanyan, Chen, Fangjun, Ding, Naiqing, Du, Shiyao, Zhou, Shujuan, Cai, Juan, Wang, Qin, Liu, Baorui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863181/
https://www.ncbi.nlm.nih.gov/pubmed/31814734
http://dx.doi.org/10.2147/OTT.S233496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863181/
https://www.ncbi.nlm.nih.gov/pubmed/31814734
http://dx.doi.org/10.2147/OTT.S233496

Ejemplares similares